IGWM
MDGL icon

ICA Group Wealth Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

ICA Group Wealth Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-90
Closed -$24K – 1091
2024
Q1 		$24K Buy
+90
New +$21.2K ﹤0.01% 717

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICA Group Wealth Management's MDGL Position: Q2 2024 in Review

ICA Group Wealth Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 90 shares — an estimated $24K sold.

ICA Group Wealth Management first reported a position in MDGL in Q1 2024 and held it in 1 quarter. The position peaked at $24K in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • ICA Group Wealth Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • ICA Group Wealth Management sold 90 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $24K.
  • ICA Group Wealth Management first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • ICA Group Wealth Management's Madrigal Pharmaceuticals position peaked at $24K in Q1 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.